AI-061

Developed for: anus cancer · bile duct cancer · cervical cancer · endometrial cancer · esophageal cancer · fallopian tube cancer · gastric cancer · gastroesophageal cancer
+8 more
· head and neck squamous cell carcinoma · hepatocellular carcinoma · melanoma · non-small cell lung carcinoma · ovarian serous adenocarcinoma · primary peritoneal carcinoma · renal cell carcinoma · urinary bladder cancer
Investigated by: Avance Clinical Pty Ltd. · OncoC4 AU Pty Ltd · OncoC4, Inc.

today NCT05858736 · Ph 1

202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05858736	Jul 2023 → Jul 2026 overdue	anus cancer, bile duct cancer, cervical cancer, endometrial cancer +12	OncoC4, Inc.	Active not recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	AI-061	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05858736 ↗
Route	Intravenous	“AI-061, 200 mg, intravenous infusion, Q3W, up to 17 cycles or approximately 1 year.” NCT05858736 ↗